Biological Activity
Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer[1].
In Vitro
Enbezotinib (compound 5) (0.3-300 nM) inhibits p-RET (y905) in RET-driven cells[1].
In Vivo
Enbezotinib (compound 5) (2-5 mg/kg; twice daily for 27 days) decreases tumor size in mice[1].
References & source
[1]. ROGERS EW, et, al. Macrocyclic compounds for treating disease. WO2019126121A1.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
